Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseasesCAMBRIDGE, Mass., May 01, 2024 -- Editas Medicine, Inc. , a...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Celgene Bristol Myers Squibb ,Bristol Myers Squibb ,Lindac Burkly ,Broad Institute Cas ,Exchange Commission ,Editas Medicine Inc ,Juno Therapeutics Inc ,Harvard University Cas ,Broad Institute ,Nasdaq ,Myers Squibb ,Chief Scientific ,Editas Medicine ,Juno Therapeutics ,Harvard University ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,